<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435447</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-ALL-2011</org_study_id>
    <nct_id>NCT01435447</nct_id>
  </id_info>
  <brief_title>Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult ALL</brief_title>
  <official_title>Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With ALL Undergoing Allogeienc Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic stem cell transplantation is potential curative therapy for adult acute
      lymphocytic leukemia (ALL). Based on our previous study, the condition with iv-busulfan
      (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity and transplantation
      mortality and long-term survival is comparable to most data reported with slightly higher
      relapse rate particularly for patients in CR2. In this study, the investigators aim to
      further improve the conditioning with Fludarabine + iv-BU and to use CTX after stem cell
      transfusion as consolidation for ALL and graft-versus-host disease (GVHD) prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with adult acute lymphocytic leukemia (ALL) received conditioning with Fludarabine +
      iv-BU. The GVHD was consisting of D+3 and D+4 CTX after stem cell transfusion. CSA will be
      added for all patients after D+5.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>transplantation related mortality</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall -survival</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FLu-Bu-Cy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLu-Bu-Cy</intervention_name>
    <description>Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.</description>
    <arm_group_label>FLu-Bu-Cy</arm_group_label>
    <other_name>Study group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult acute lymphocytic leukemia in 1st or second remission

          -  age 18-60 years

          -  with inform consent

          -  no contraindication for allogeneic transplantation: active infection, allergy to
             FLu/Bu/CTX, liver and renal function damage

          -  HLA matched related (6/6), unrelated donors (at least 8/10) or mismatched related
             donor (haplo)

        Exclusion Criteria:

          -  age less than 18 years or over 60 years

          -  liver function/renal function damage (over 2 X upper normal range)

          -  with mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Hu, m.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU, M.D.</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tang Wei, M.D.</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601816</phone_ext>
    <email>weiwei_tang@yaoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood and Marrow Transplantation Center, Rui Jin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601878</phone_ext>
      <email>hujiong@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Center, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>conditioning</keyword>
  <keyword>fludarabine</keyword>
  <keyword>busulfan</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

